Pulmonary autograft for mitral valve replacement in infants: the Ross-Kabbani operation

Alessandro Frigiola1, Toni Badia, Giuseppe Pomè

  • 1Centro Cardiovascolare Malan, Istituto Policlinico San Donato, San Donato Milanese, Italy. alfrigio@tin.it

Insights

The Ross-Kabbani procedure using a pulmonary autograft successfully treated severe mitral valve dysplasia in two infants. This surgical approach offered a viable solution for critical heart failure in very young patients.

Area of Science:

  • Cardiology
  • Pediatric Cardiac Surgery
  • Valvular Heart Disease

Background:

  • Infants with severe mitral valve dysplasia often present with critical heart failure, necessitating surgical intervention.
  • Traditional surgical options like repair or mechanical prosthesis implantation are frequently unsuitable for very young infants due to anatomical limitations and anticoagulation challenges.

Observation:

  • Two infants, aged 6 and 2.5 months, presented with severe mitral valve dysplasia, leading to significant valvular insufficiency and heart failure.
  • The specific anatomical features of their mitral valves precluded repair, and mechanical prostheses were contraindicated due to age and anticoagulation concerns.

Findings:

  • A Ross-Kabbani intervention, involving pulmonary autograft implantation in the mitral position and a pulmonary homograft, was performed in both infants.
  • Both patients experienced a postoperative course free of major complications.
  • Short-term follow-up demonstrated good function of the pulmonary autograft in the mitral position.

Implications:

  • The Ross-Kabbani procedure with a pulmonary autograft represents a promising surgical strategy for managing severe mitral valve dysplasia in infants when other options are not feasible.
  • This technique may offer a durable solution, avoiding the long-term complications associated with mechanical valves in pediatric populations.
  • Further research and long-term follow-up are warranted to fully assess the durability and efficacy of this approach in pediatric valvular heart disease.